National Graphite Corp. (OTCPK: NGRC)
Health Care · Biotechnology · US
$0.02
+5.24% today · +5.2% 1Y
National Graphite Corp. (OTCPK: NGRC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.41M and employs 1 people.
Over the last twelve months the share price has gained 5.2%, trading between 0.01 and 0.05.
Tweenvest scores National Graphite Corp. across four factors: quality 18/100, value 37/100. Its strongest factor is value.
NGRC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.41M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 2.90
- 52-week high
- $0.05
- 52-week low
- $0.01
- Avg volume (3M)
- —
- Shares outstanding
- 154.31M
- Employees
- 1
- Next earnings
- —
About National Graphite Corp.
National Graphite Corp. (NGRC), operating through its subsidiary Biotech Development Corp., functions as a biopharmaceutical enterprise specializing in risk and cost-sharing models. The company establishes partnerships with clinical-stage firms dedicated to developing novel biological entities or innovative therapeutic platforms. These collaborations aim to address a wide spectrum of health conditions, encompassing common illnesses, rare disorders, and those with significant unmet medical requirements. Among its key pipeline developments is ELAFIN, a drug candidate identified as a human-identical protein. ELAFIN is being developed specifically for the management of postoperative inflammatory complications. The advancement of ELAFIN is further supported by a collaboration agreement with Proteo Inc. Founded in 2006, National Graphite Corp. was formerly known as Lucky Boy Silver Corporation until it officially adopted its current name in May 2012. The company maintains its operational headquarters in Duesseldorf, Germany.
- ISIN
- US6362682030
- Founded
- 2006
- Listed since
- Aug 3, 2012
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Tissue Repair LtdASX: TRP | $3.56M | AU$0.09 | -5.56% |
| Dermata Therapeutics, Inc.NasdaqCM: DRMA | $3.46M | $0.86 | -15.69% |
| Lunai Bioworks Inc.NasdaqCM: LNAI | $3.43M | $0.68 | -44.68% |
| Ernexa Therapeutics Inc.NasdaqCM: ERNA | $3.41M | $2.09 | -12.92% |
| Chosa Oncology ABNGM: CHOSA | $3.31M | Skr— | — |
| Affymax, Inc.OTCPK: AFFY | $3.10M | $0.04 | +2500.00% |
| Calidi Biotherapeutics, Inc.NYSEAM: CLDI | $3.09M | $0.84 | -18.74% |
| Restart Life Sciences Corp.CNSX: HEAL | $3.06M | CA$0.07 | -6.67% |
Figures last refreshed Oct 18, 2026.